Last reviewed · How we verify
NCT06823505
Lung Cancer Patients and Parent-child Interaction Experience and Process
trial testing structured questionnaire in Lung Cancer Patients in 109 participants. Terminated before completion.
21 January 2025
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 109 |
| Start date | 17 December 2023 |
| Primary completion | 21 January 2025 |
| Estimated completion | 21 January 2025 |
| Sites | 2 locations across Taiwan |
Drugs / interventions tested
- structured questionnaire
Conditions studied
- Lung Cancer Patients — all drugs for Lung Cancer Patients →
- Parent-child Interaction — all drugs for Parent-child Interaction →
Sponsor
National Taiwan University Hospital
Who can join
Adults 40 to 64, any sex, with Lung Cancer Patients or Parent-child Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Type of study: The goal of this observational study is to explore the relationship between patients with advanced lung cancer and their parent-child interactions during the treatment process, and to understand the impact of the degree of self-differentiation of parents with advanced lung cancer on the physical and mental health of their children. The main questions it aims to answer are: 1. To explore the post-illness adjustment process of patients with advanced lung cancer and the changes in the parent-child relationship among adolescents. 2. To explore the changes in demographic factors-self-belief, mental health, and self-efficacy among patients with advanced lung cancer-and the parent-child relationship among adolescents. 3. Explore the family resilience of patients with advanced lung cancer - family peer relationships, and the interaction between parent-child relationships among adolescents.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06823505
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer Patients
Currently open trials in the same condition.
- NCT07281300 — Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer · NA · recruiting
- NCT07024433 — Tubeless Anesthesia in Preventing Lung Complications in Patients Undergoing Surgery for Early-Stage Lung Cancer · NA · recruiting
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06823505 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06823505.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing